DiscoveryProbe™ FDA-approved Drug Library: A Benchmark for High-Throughput Drug Screening and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) comprises 2,320 bioactive compounds approved by major regulatory authorities or listed in pharmacopeias, supporting high-throughput and high-content screening (HTS/HCS) (product page). The collection includes compounds with well-characterized mechanisms, such as doxorubicin, metformin, and atorvastatin, facilitating drug repositioning and novel target discovery (Rashid et al., 2021). Each compound is provided as a pre-dissolved 10 mM DMSO solution, stable for up to 24 months at -80°C. The library supports robust, reproducible research across oncology, neurodegeneration, and pharmacology. Its format and regulatory breadth enable systematic screening with minimized logistical and scientific barriers.

Biological Rationale

Drug discovery increasingly relies on systematic, high-throughput approaches to identify effective compounds and therapeutic targets. FDA-approved drugs are attractive for repurposing because their safety and pharmacokinetics are well-characterized (Rashid et al., 2021). The DiscoveryProbe™ FDA-approved Drug Library leverages this by assembling a wide array of molecules with established clinical utility. This enables researchers to rapidly test hypotheses in disease models—such as triple-negative breast cancer (TNBC) or neurodegenerative disorders—where standard therapies are limited or ineffective. By targeting multiple mechanisms (e.g., receptor modulation, enzyme inhibition), the library facilitates the identification of new uses for existing drugs, reduces development timelines, and supports precision medicine workflows.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

This compound collection encompasses diverse mechanisms of action (MoA), including:

• Receptor agonists and antagonists: e.g., β-blockers, opioid antagonists.
• Enzyme inhibitors: e.g., kinase inhibitors, protease inhibitors.
• Ion channel modulators: e.g., calcium channel blockers.
• Signal pathway regulators: e.g., PI3K/mTOR inhibitors, nuclear export inhibitors.

By including both small molecules and biologically active drugs, the library covers a vast range of cellular processes. For example, KPT-330 (selinexor), an XPO1 inhibitor, and GSK2126458, a dual PI3K/mTOR inhibitor, have been shown to synergistically reduce tumor burden in basal-like TNBC models (Rashid et al., 2021). The presence of such compounds in the DiscoveryProbe™ library allows comprehensive mechanism-driven screening in a single, unified workflow.

Evidence & Benchmarks

• Contains 2,320 unique, clinically approved bioactive compounds from FDA, EMA, HMA, CFDA, and PMDA, ensuring global regulatory coverage (product page).
• HTS of 1,363 clinically used drugs, comparable to the DiscoveryProbe™ collection, identified 10 promising candidates for TNBC, including KPT-330 and GSK2126458 (Rashid et al., 2021).
• Combination of KPT-330 and GSK2126458 reduced tumor burden in four basal-like TNBC patient-derived xenograft (PDX) models, outperforming monotherapy (in vivo, mouse, 30-day endpoint) (Rashid et al., 2021).
• All compounds are supplied as pre-dissolved 10 mM DMSO solutions, stable for 12 months at -20°C and up to 24 months at -80°C (product page).
• Library formats include 96-well microplates, deep well plates, and 2D barcoded screw-top tubes, enabling flexible integration into HTS/HCS workflows (product page).
• HTS using similar libraries has enabled rapid identification of synergistic drug combinations and cytotoxic agents in difficult-to-treat cancers (Rashid et al., 2021).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is designed for:

• Drug repositioning screening: Re-evaluating approved drugs for new indications based on mechanistic or phenotypic screens.
• Pharmacological target identification: Elucidating novel molecular targets via response profiling.
• Cancer research drug screening: Testing drug efficacy and synergism in models such as TNBC and other tumor types (Rashid et al., 2021).
• Neurodegenerative disease drug discovery: Screening for modulators of pathways implicated in Alzheimer's, Parkinson's, and related disorders.
• Signal pathway regulation and enzyme inhibitor screening: Identifying compounds that modulate key intracellular cascades.

For an in-depth discussion of antimicrobial resistance and signal pathway regulation, see this article—the current review expands on high-throughput oncology and neurodegeneration applications beyond antimicrobial contexts. For a translational research perspective, this resource bridges discovery and clinical translation, whereas the present article emphasizes benchmarking and workflow standardization. For workflow optimization and troubleshooting, see here; our discussion details regulatory breadth and evidence integration.

Common Pitfalls or Misconceptions

• Not all compounds are suitable for every disease context: Mechanism-specific limitations must be considered; e.g., kinase inhibitors may not affect non-kinase-driven diseases.
• HTS/HCS does not guarantee clinical translatability: Hits require downstream validation in relevant preclinical models.
• Compound solubility outside DMSO is not assured: Some drugs are poorly soluble in aqueous buffers, affecting certain assays.
• Resistance mechanisms may limit efficacy: Efficacious drugs in vitro may be circumvented by tumor or microbial resistance pathways.
• Library composition reflects approved/clinically used agents: It does not include investigational or preclinical-only compounds.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is optimized for rapid deployment in academic, translational, and industrial settings. Compounds are provided as 10 mM DMSO solutions, dispensed into 96-well microplates, deep well plates, or individually barcoded screw-top tubes. Shipping is performed on blue ice for evaluation samples and at room temperature or on blue ice for larger sizes, as requested. Upon receipt, compounds should be stored at -20°C (for up to 12 months) or -80°C (for up to 24 months) to ensure stability. The pre-dissolved format eliminates the need for reconstitution, minimizing pipetting errors and batch variability. Users can directly transfer aliquots for HTS (using automated liquid handling) or HCS (with imaging-based endpoints). This enables seamless integration into established screening pipelines and supports parallel analyses such as transcriptomics or proteomics for hit validation.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) serves as a gold standard for mechanism-driven drug screening and repositioning. Its comprehensive, regulatory-validated compound set, stable pre-dissolved format, and flexible workflow integration enable reproducible, high-impact discovery across cancer, neurodegenerative, and pharmacological research. As new disease models emerge and screening technologies advance, this resource will continue to accelerate the identification of clinically actionable targets and therapies (DiscoveryProbe™ FDA-approved Drug Library). For a systems biology perspective on pathway regulation, see here—this review focuses on clinical and workflow benchmarking.